Additionally, it suggests that SIRT1 inhibition combined with ICB therapy may ameliorate the unresponsiveness of BAP1-deficient pancreatic cancer to single-agent immunotherapy. This evidence concerns the gene SIRT1 and pancreatic neoplasm.